Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) delivers cutting-edge gene therapies targeting rare central nervous system disorders through innovative AAV vector technology. This news hub provides investors and researchers with timely updates on clinical advancements, strategic partnerships, and operational developments shaping the company's trajectory in genetic medicine.
Access authoritative reporting on PASG's lead programs including PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia. Our curated news collection features regulatory milestones, trial data disclosures, and analysis of licensing agreements with academic and industry partners.
Key updates cover three critical areas: clinical trial progress across neurodegenerative targets, research collaborations enhancing therapeutic platforms, and strategic operational decisions supporting sustainable development. Bookmark this page for consolidated access to PASG's evolving position in gene therapy innovation.
Passage Bio (NASDAQ: PASG) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its PBFT02 program for FTD-GRN patients. Interim data showed promising results, with Dose 1 PBFT02 increasing CSF progranulin levels from below 3 ng/mL to 13-27 ng/mL at six months and 22-34 ng/mL at 12 months.
The company has enrolled its first patient for Dose 2 PBFT02, which is 50% lower than Dose 1. Financial results show cash position of $76.8 million as of December 31, 2024, with runway extended into Q1 2027. Net loss for 2024 was $64.8 million ($1.07 per share), improved from $102.1 million in 2023. R&D expenses decreased to $40.2 million from $61.4 million, while G&A expenses reduced to $25.0 million from $41.6 million year-over-year.
Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company specializing in neurodegenerative diseases, has announced its participation in two major upcoming investor conferences.
The company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025, at 9:10 a.m. ET, and the Leerink Global Biopharma Conference in Miami on March 12, 2025, at 8:00 a.m. ET. Both events will feature management presentations and investor meetings.
Interested parties can access live webcasts of the presentations through the Investors & Media section of Passage Bio's website at investors.passagebio.com. Replay recordings will remain available for 30 days after each event.
Passage Bio (NASDAQ: PASG) reported updated interim data from its Phase 1/2 upliFT-D clinical trial for PBFT02, targeting frontotemporal dementia (FTD) with granulin mutations. The data showed consistent increases in CSF PGRN expression and early signs of reduced disease progression compared to natural history data.
The company plans to evaluate a second dose that is 50% lower than Dose 1 for subsequent FTD-GRN and FTD-C9orf72 patients. Key upcoming milestones include reporting 12-month data from Dose 1 and interim data from Dose 2 in 2H 2025, with plans to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026.
Passage Bio has successfully completed process development for a high-productivity, suspension-based manufacturing process for PBFT02. The company is transitioning to an outsourced analytical testing model and reducing its workforce by 55%, extending its cash runway into Q1 2027.
Passage Bio (NASDAQ: PASG) reports Q3 2024 financial results and business updates. The company has enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with dosing progressing as planned. Updated interim data from Cohort 1 showed PBFT02 was well-tolerated with elevated CSF progranulin levels for up to 12 months. Financial highlights include cash position of $84.8 million, R&D expenses of $8.7 million (down from $15.1 million YoY), and net loss of $19.3 million ($0.31 per share). The company expects current cash to fund operations through Q2 2026.
Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company specializing in neurodegenerative diseases, has announced its participation in the upcoming Guggenheim Securities Healthcare Innovation Conference. Will Chou, M.D., the company's president and CEO, will deliver a presentation on November 13, 2024, at 2:30 p.m. ET. The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for 30 days after the event.
Passage Bio (NASDAQ: PASG) presented preclinical and interim clinical data for PBFT02, their gene therapy treatment for frontotemporal dementia (FTD-GRN), at the ESGCT 31st Annual Conference. Key findings showed that AAV1 vector achieved superior human progranulin levels compared to other vectors, and PBFT02 improved lysosomal histopathology and reduced neuroinflammation in test subjects.
The interim clinical data from the upliFT-D trial demonstrated that PBFT02 was well-tolerated and produced consistent, durable increases in CSF progranulin levels, maintained up to 12 months post-administration. The therapy showed promising results in achieving widespread vector distribution throughout the nervous system.
Passage Bio, a clinical stage genetic medicines company focused on neurodegenerative diseases, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. Will Chou, M.D., the company's president and CEO, will present on Tuesday, October 1, 2024, at 8:30 a.m. ET.
The presentation will be accessible via a live webcast on the Investors & Media section of Passage Bio's website at investors.passagebio.com. For those unable to attend the live event, a replay will be available for 30 days following the presentation.
Passage Bio is traded on the NASDAQ under the ticker symbol PASG.
Passage Bio (Nasdaq: PASG) will present updated data from its Phase 1/2 upliFT-D clinical trial of PBFT02, a gene therapy for frontotemporal dementia (FTD) with granulin mutations, at the 14th International Conference on Frontotemporal Dementias on September 20, 2024. The interim results from Cohort 1 (n=5) show that Dose 1 of PBFT02 was well-tolerated in patients receiving an enhanced immunosuppression regimen, with no serious adverse events observed.
Key findings include:
- Robust and durable increase in CSF progranulin (PGRN) expression, up to 6-fold at one month and 10-fold at six months
- CSF PGRN levels exceeded healthy adult control ranges
- Elevated CSF PGRN levels sustained up to 12 months post-treatment
- No evidence of dorsal root ganglion toxicity or clinically significant immune responses
These results suggest PBFT02's potential as a best-in-class progranulin-raising therapy for neurodegenerative diseases.
Passage Bio (Nasdaq: PASG) has appointed Tom Kassberg to its Board of Directors and Audit Committee. Kassberg, currently Chief Business Officer and Executive VP at Ultragenyx, brings extensive experience in strategic planning and corporate development. His background includes leadership roles at Proteolix, InterMune, Plexxikon, and SUGEN. Passage Bio CEO Will Chou highlighted Kassberg's expertise in advancing gene therapies for rare diseases, which aligns with the company's focus on neurodegenerative diseases. Kassberg expressed enthusiasm for joining Passage Bio, particularly noting the progress of the PBFT02 program and its potential expansion into additional indications.
Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company focusing on neurodegenerative diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's president and CEO, Will Chou, M.D., is scheduled to present on Monday, September 9, 2024, at 7:00 a.m. ET.
Investors and interested parties can access a live webcast of the presentation through the Investors & Media section of Passage Bio's website at investors.passagebio.com. For those unable to attend the live event, a replay will be available for 30 days following the presentation.
